1. Tirzepatide yielded 20.2% mean reduction in body weight over 72 weeks compared to semaglutide in adult patients with obesity.
2. Greater weight reductions were associated with improved cardiometabolic risk factors. 
3. Tirzepatide was superior to semaglutide in the reduction of body weight and waist circumference.
4. Gastrointestinal adverse events were more frequent with tirzepatide, but both medications had consistent safety profiles.
5. The trial population was representative of the adult patients with obesity, showing potential benefits for females.

Source: The New England Journal of Medicine